Proposed issue of securities
Announcement Summary
For personal use only
Entity name
NEUROTECH INTERNATIONAL LIMITED
Announcement Type
New announcement
Date of this announcement
3/3/2022
The Proposed issue is:
A placement or other type of issue
Total number of +securities proposed to be issued for a placement or other type of issue
Maximum Number of | ||
ASX +security code | +Security description | +securities to be issued |
New class-code to be | Unlisted Options ($0.08, 10 March 2024) | 5,000,000 |
confirmed | ||
New class-code to be | Unlisted Options ($0.12, 10 March 2024) | 5,000,000 |
confirmed | ||
New class-code to be | Unlisted Options ($0.16,10 March 2024) | 5,000,000 |
confirmed |
Proposed +issue date
10/3/2022
Refer to next page for full details of the announcement
Proposed issue of securities | 1 / 8 |
Proposed issue of securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of +Entity
NEUROTECH INTERNATIONAL LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 | Registered Number Type | Registration Number |
ACN | 610205402 | |
1.3 | ASX issuer code | |
NTI | ||
1.4 The announcement is | ||
New announcement | ||
1.5 | Date of this announcement | |
3/3/2022 | ||
1.6 | The Proposed issue is: | |
A placement or other type of issue |
Proposed issue of securities | 2 / 8 |
Proposed issue of securities
Part 7 - Details of proposed placement or other issue
only | ||||||
Part 7A - Conditions | ||||||
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other | ||||||
type of issue can proceed on an unconditional basis? | ||||||
use | No | |||||
Part 7B - Issue details | ||||||
Is the proposed security a 'New | Will the proposed issue of this | |||||
class' (+securities in a class that is | +security include an offer of | |||||
not yet quoted or recorded by ASX) | attaching +securities? | |||||
personal | or an 'Existing class' (additional | No | ||||
securities in a class that is already | ||||||
quoted or recorded by ASX)? | ||||||
New class | ||||||
Details of +securities proposed to be issued | ||||||
ISIN Code (if Issuer is a foreign company and +securities are non CDIs) | ||||||
Have you received confirmation from | Will the entity be seeking quotation | |||||
ASX that the terms of the proposed | of the 'new' class of +securities on | |||||
+securities are appropriate and | ASX? | |||||
equitable under listing rule 6.1? | No | |||||
No | ||||||
ASX +security code | +Security description | |||||
New class-code to be confirmed | Unlisted Options ($0.08, 10 March 2024) | |||||
For | ||||||
+Security type | ||||||
Options | ||||||
Number of +securities proposed to be issued 5,000,000
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
No
Proposed issue of securities | 3 / 8 |
Proposed issue of securities
Please describe the consideration being provided for the +securities
The Company has agreed to issue 5,000,000 options to CEO, Alexandra Andrews, as the first tranche of the equity based component to her remuneration package.
Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
only
Will all the +securities issued in this class rank equally in all respects from their issue date?
Yes
Options details | |||||
use | +Security currency | Exercise price | Expiry date | ||
AUD - Australian Dollar | AUD 0.0800 | 10/3/2024 | |||
Details of the type of +security that will be issued if the option is exercised | |||||
NTI : ORDINARY FULLY PAID | |||||
personal | Number of securities that will be issued if the option is exercised | ||||
not yet quoted or recorded by ASX) | attaching +securities? | ||||
One fully paid ordinary share | |||||
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities | |||||
proposed to be issued or provide the information by separate announcement. | |||||
Subject to vesting conditions, the Options will be exercisable at $0.08 and expire two years from their date of issue. The | |||||
Options will vest 12 months after the commencement date of Dr Andrews as CEO, subject to Dr Andrews remaining | |||||
continually employed by the Company on this date. | |||||
Refer to the ASX release dated 3 March 2022 for further information. | |||||
Is the proposed security a 'New | Will the proposed issue of this | ||||
class' (+securities in a class that is | +security include an offer of | ||||
For | or an 'Existing class' (additional | No | |||
securities in a class that is already | |||||
quoted or recorded by ASX)? New class
Details of +securities proposed to be issued
ISIN Code (if Issuer is a foreign company and +securities are non CDIs)
Have you received confirmation from | Will the entity be seeking quotation |
ASX that the terms of the proposed | of the 'new' class of +securities on |
+securities are appropriate and | ASX? |
Proposed issue of securities | 4 / 8 |
Proposed issue of securities
equitable under listing rule 6.1? | No | |||
No | ||||
ASX +security code | +Security description | |||
New class-code to be confirmed | Unlisted Options ($0.12, 10 March 2024) | |||
only | ||||
+Security type | ||||
Options | ||||
Number of +securities proposed to be issued | ||||
5,000,000 | ||||
Offer price details | ||||
use | Are the +securities proposed to be issued being issued for a cash consideration? | |||
No | ||||
Please describe the consideration being provided for the +securities | ||||
The Company has agreed to issue 5,000,000 options to CEO, Alexandra Andrews, as the second tranche of the equity | ||||
based component to her remuneration package. | ||||
personal | Please provide an estimate of the AUD equivalent of the consideration being | |||
provided for the +securities | ||||
NTI : ORDINARY FULLY PAID | ||||
Will all the +securities issued in this class rank equally in all respects from | ||||
their issue date? | ||||
Yes | ||||
Options details | ||||
+Security currency | Exercise price | Expiry date | ||
AUD - Australian Dollar | AUD 0.1200 | 10/3/2024 | ||
Details of the type of +security that will be issued if the option is exercised | ||||
For | Number of securities that will be issued if the option is exercised | |||
One fully paid ordinary share | ||||
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities | ||||
proposed to be issued or provide the information by separate announcement. | ||||
Subject to vesting conditions, the Options will be exercisable at $0.12 and expire two years from their date of issue. The | ||||
Options will vest 18 months after the commencement date of Dr Andrews as CEO, subject to Dr Andrews remaining | ||||
continually employed by the Company on this date. | ||||
Refer to the ASX release dated 3 March 2022 for further information. | ||||
Proposed issue of securities | 5 / 8 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Neurotech International Ltd. published this content on 03 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 March 2022 07:39:01 UTC.